CAI vs TGTX: which is the better buy in 2026?
On Alexandria's Compass, TG Therapeutics, Inc. has the edge with a 90/100 score versus 88/100 for CAI. Here is how they stack up, factor by factor.
Caris Life Sciences, Inc.
NASDAQ:CAI
Sequencing-everything oncology platform trading at half its IPO price while volume compounds 78% and FCF turned positive.
Full CAI analysisTG Therapeutics, Inc.
NASDAQ:TGTX
BRIUMVI is becoming the default subcutaneous anti-CD20 for MS, and the market still prices it like a one-product also-ran.
Full TGTX analysisFactor by factor
Get head-to-heads like this, free
Join the Alexandria e-letter for Compass verdicts, earnings intelligence, and the contrarian calls the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is CAI or TGTX the better buy in 2026?
By Compass Score, TG Therapeutics, Inc. (NASDAQ:TGTX) edges it at 90/100 versus 88/100 for CAI. Both scores update weekly and reflect a contrarian, forward-looking read, not a recommendation.
How does Alexandria compare CAI and TGTX?
Each company is scored 1-100 on eight factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The Compass Score is the composite, and the comparison below shows where each name wins factor by factor.
Compass Scores are proprietary editorial research from publicly available data, not investment advice or a recommendation regarding any security. Rankings update weekly.